Work

First-line (1L) tislelizumab (TIS) plus chemotherapy (CT) vs placebo (PBO) plus CT in advanced/metastatic esophageal squamous cell carcinoma (ESCC): RATIONALE-306 Japanese subgroup analysis with longer follow-up.

Year: 2025

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2025.43.4_suppl.420

Authors: Takashi Kojima, Takashi Ogata, Ryu Ishihara, Hiroki Hara, Tianmo Sun, Sheng Xu, Ken Kato

Institutions: National Cancer Centre Japan, National Cancer Center Hospital East, Kanagawa Cancer Center, Osaka International Cancer Institute, Saitama Prefecture, Saitama Cancer Center, BeiGene (China), National Cancer Center Hospital

Language: English

Topic: Esophageal Cancer Research and Treatment

Subfield: Surgery

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4406868682

Cites:

Cited by: 1

Related to: 10